{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019262","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.686788+00:00","generated_at":"2026-06-02T00:58:48.018858+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Serina Therapeutics Q1 net loss $9.4M; going concern substantial doubt","bullets":["Net loss of $9.4M ($3.38/share) vs net income of $1.7M in Q1 2023.","Cash, cash equivalents, and restricted cash total $8.8M as of March 31, 2024.","Company states cash not sufficient for 12 months, raising substantial doubt about going concern.","Juvenescence line of credit increased by $2.4M in March and $525k in May; total owed $10.4M.","Lead candidate SER-252 IND submission planned for 2025; Dr. Simba Gill appointed Executive Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019262","json":"https://secwatch.observer/filing/0001493152-24-019262.json","markdown":"https://secwatch.observer/filing/0001493152-24-019262.md","text":"https://secwatch.observer/filing/0001493152-24-019262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224019262/0001493152-24-019262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224019262/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:58:48.018858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86c75a5d733c5ecde3d32328133ee848b7815e4b","claim":"Serina Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $5,000 and $30,000 for the first quarter of 2024 and in the same period in 2023, respectively, net income $9.4 million, or ($3.38) per share (basic and diluted), EPS ($3.38) per share (basic and diluted).","evidence_excerpt":"On May 14, 2024, the Company announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224019262/0001493152-24-019262-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$5,000 and $30,000 for the first quarter of 2024 and in the same period in 2023, respectively"},{"label":"Net income","value":"$9.4 million, or ($3.38) per share (basic and diluted)"},{"label":"EPS","value":"($3.38) per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}